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planned hospitalization. Full course of radiotherapy can be 
safely used in older patients but they have a low tolerance to 
chemotherapy and frequently require dose-reduction; the 
effect of this chemotherapy is uncertain.  
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Purpose/Objective: Various guidelines, including UK NICE 
guidance recommend a minimum of 74 Gy for prostate cancer 
radiotherapy. So we escalated prostate radiation dose to 74 
Gy (2Gy per #) in our department. We previously found that 
elderly patients were able to tolerate radiotherapy (RT) very 
well when median RT dose was 70 Gy (Data published 2006). 
Following RT dose escalation, we analysed our prospectively 
collected, rectal toxicity data in our department. 
Materials and Methods: All patients (pts) treated with 
prostate radiotherapy between August 2010 and July 2011, 
were identified from MOSAIC Software (Elekta). Pts who had 
prostate-bed radiotherapy, whole pelvis RT or HDR boost 
were excluded. The regional ethics committee advised that 
formal ethics approval was not necessary. 
Results: 132 patients were identified; median age was 70.5 
years, ( range 53 to 81 yrs). Median PSA was 13 (range 4.2 to 
133). Gleason scores: G6 4.5%, G7 51.5%, G8 21.2%, G9 18.2% 
G10 2.3% (missing data 2.3%). Tumour stage: T1 8.3%, T2 
55.3%, T3 32.6%, T4 0% (missing data 3.8%). Median total 
radiation dose was 74Gy (range 66Gy to 78Gy). (66 Gy is an 
outlier due to dosimetric problems caused by bilateral hip 
replacement). Age was significantly associated with rectal 
toxicity. Patients aged over 75 were almost 3.5 times more 
likely to develop ≥ grade 2 toxicity (p=0.026). Absolute total 
rectal volume outlined ( in cc) was also significantly 
associated with rectal toxicity. Pts having maximum rectal 
volume of more than 46cc were 3.8 times more likely to 
develop ≥ grade 2 toxicity (p=0.03 chi squared test). The 
rectal DVH parameters for 30Gy, 50Gy, and 60Gy were 
significantly associated with rectal toxicity .(p=0.038; 
p=0.016 and p=0.002 respectively). The absolute-volume 
parameters were consistently and better correlated with 
rectal toxicity than percentage-volume parameters. Median 
absolute rectal volume for patients with ≥grade 2 acute 
rectal toxicity was significantly higher than for those with 
grade 0/1 toxicity (p=0.018). By contrast, the difference 
between median percentage-Volume was not significant 
(p=0.345). The following Absolute-volume DVH constraints 
were most significantly correlated with rectal toxicity. 
V30≤42cc, V50≤40cc, V60≤35cc. 
Conclusions: Our real world data, from an unselected 
population of pts indicate elderly pts ( > 75 years) are at 
increased risk of rectal toxicity. If rectal DVH parameters are 
not optimal, elderly prostate pts should be considered for 
radiation dose reduction as patient preference studies 
indicate that lot of patients prefer lower toxicity over 
efficacy. (van Tol-Geerdink et al. J Clin Oncol. 2006: 24: 
4581). 
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Purpose/Objective: The incidence of cancer in the elderly is 
expected to rise . For example in the USA it is estimated that 
it will rise by 67% between 2010 to 2030. This is a 
retrospective analysis audit on radiotherapy to the very 
elderly defined as patients above 80 years old from Jan 2012 
until Dec 2013. We hope to analyse the radiotherapy intent; 
tumour site analysis and median survival days from the last 
fraction of radiotherapy. With these understanding, we hope 
to be able to further better or understanding and plan 
management for our very elderly who are under our care in 
future. 
Materials and Methods: We retrospectively collected and 
analysed the data from our Aria database for all patients 
above 80 years old on the day they finished treatment from 
January 2012 until Dec 2013. 
Results: We treated 1571 patients who were very elderly 
during these analysed 2 years. 40% of our very elderly were 
treated with radical intent. Nearly 25% of them were patients 
treated for Breast Cancer followed by Lung Cancer (20%). 
There was nearly an equal distribution with 51% of them 
being male patients. The median days from time of last 
fraction of radiotherapy to death was 129 days with a 
maximum of 826 days at time of analysis. Palliative 
treatments to the very elderly were mainly palliation for 
bone metastases and lung/ chest palliation. 
Conclusions: There is a high proportion of the very elderly 
treated with radical intent with radiotherapy; with Breast 
and Lung Cancer being the highest malignant cause. There 
was a fairly equal sex distribution between those treated for 
radiotherapy in the very elderly. We need to further analyse 
these data to provide a more meaning insight in order to 
improve and adequately support our very elderly requiring 
treatment. 
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Purpose/Objective: the incidence of esophageal cancer is 
increasing. Additionally, an increasing number of patients are 
older than 75 years. Since the publication of the CROSS trial 
in 2012, preoperative chemoradiation (CRT) followed by 
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surgery is the standard treatment for potentially resectable 
esophageal cancer. Patients aged over 75 years or with a 
tumor length of more than 8 cm were not included in the 
CROSS trial. In clinical practice, these patients are also 
treated according to the CROSS strategy, when considered fit 
enough. The aim of this study is to analyze the effectiveness 
and toxicity of preoperative CRT followed by resection for 
patients who do not meet the CROSS criteria because of age 
or tumor length. 
Materials and Methods; patients treated from 2005 to 
November 2013 in the Esophageal Centre East Netherlands 
according to the CROSS trial were included. Patients were 
divided into two groups; group I 'meeting criteria CROSS' 
(n=110) and group II '>75 years and or tumor length > 8 cm' 
(n=16). Primary endpoints were differences in disease 
specific and overall survival and secondary endpoints were 
toxicity, treatment interruptions and residual tumor volume 
after CRT. 
Results: in this small population, the effectiveness did not 
seem to differ between patients who did and did not meet 
the inclusion criteria of the CROSS trial. Similar disease 
specific survival rates were found, although overall survival 
was shorter for patients who were not eligible for the CROSS 
trial (3.6 vs. 6.2 years, p=0,02). Among a subgroup of 
patients aged over 75 years (n=9), more adverse effects of 
CRT were reported (89% vs 65%, relative risk 1,4 (95% CI 1,1-
1,8)), as were postoperative complications (100% vs 65%, 
relative risk 1,5 (95% CI 1,3-1,8)). Also, treatment was more 
often interrupted among older patients 33% vs 6%( relative 
risk 5,8 (95% CI 1,7-19,5)). In the subgroup tumor length > 8 
cm (n=7) we did not find a difference in toxicity. However, a 
lower percentage residual tumor after CRT was found in the 
subgroup >75 years compared to group I (50% vs 19%, relative 
risk 0,2 (95% CI 0,1-1,0)). 
Conclusions: we found no obvious differences in the 
effectiveness of preoperative CRT followed by resection 
between patients who did and did not meet the inclusion 
critera of the CROSS trial based on age and tumor length. 
Patients aged >75 years have an increased risk of adverse 
effects and postoperative complications. 
Discussion: our findings based on a retrospective evaluation 
of a small number of patients should lead to further 
prospective research. 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the 
most common malignant primary brain tumor. Depending on 
the increase of elderly patient population, the incidence of 
GBM in elderly patients is rising and identification of 
prognostic factors is very important for treatment 
management. 50 years of age is considered as a prognostic 
limit for malignant gliomas. In this study, we aimed to 
evaluate clinical prognostic factors in patients aged 50 and 
older. 
Materials and Methods: Clinical prognostic factors of 73 GBM 
patients aged 50 and older, are evaluated retrospectively. 
Results: Mean survival was 5.2 months (0.1- 33.23 months). 
30 patients (41.1%) were female and 43 patients (58.9%) were 
male. Of the 73 patients, 36 (49.3%) were in the range of 50 
to 59 years old and 37 (50.7%) were aged 60 and above. 
Primary tumors were confined to a single lobe in 36 patients 
(49.3%). Nearly total resection of tumor had been performed 
in 26 patients (35.6%). Average values of tumor diameter and 
residual tumor diameter were 4.82 cm (3-8 cm) and 1 cm (0-
8cm), respectively. 31 patients (42.4%) had WHO 
performance score of 0 or 1. In univariate analysis, factors 
that affect the survival negatively were: poor WHO 
performance status (p=0.001), ≥60 age (p=0.04), ≥1cm 
residual tumor diameter (p=0.012), ≥40 days of Radiotherapy 
(RT) period (0.002),  
Conclusions: Standard treatment of GBM consists of surgery, 
radiotherapy, and chemotherapy with temozolomide. But 
optimal treatments cannot be performed in all elderly 
patients. In this study, it has been determined that the 
maximal resection (as much as possible) of the tumor affects 
significantly the survival in elderly patients. 
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Purpose/Objective: To evaluate technique, toxicity and 
results of stereotactic body radiation therapy (SBRT) for 
primary or metastatic lung tumors in patients over 75 years 
old. 
Materials and Methods: Between 2002 and 2014, 73 elderly 
patients (61 men and 12 women) with 85 lung tumors: 65 
primary and 20 oligometastatic were treated using SBRT. 
Treatment outcomes, toxicity and technique were analyzed 
retrospectively. 
SBRT involved: Computed tomography (CT) slow-scan 
simulation with immobilization devices, contouring the target 
volume in 3 sets of CTs, superimposing the volumes in the 
planning system to represent the internal target volume 
(ITV), dose calculation using heterogeneity correction and 
assuring very conformal dose distribution and a steep fall-off 
of the radiation dose outside treatment volume and radiation 
delivery with multiple static non-coplanar beams and arc 
therapy. The prescribed dose was ablative, either 3 fractions 
of 14-16 Gy each or a single 30-Gy fraction (corresponding to 
biologically equivalent doses > 100). Dose constraints were 
set for surrounding organs at risk.  Toxicity and radiologic 
response were assessed in follow-up visits, using conventional 
criteria (RTOG, EORTC scores and radiologist reviewed 
reports). Survival rates and cumulative incidences of 
toxicities were calculated by actuarial and Kaplan-Meier 
method. 
Results: Median patient age was 80 years (75-88). Before 
treatment all patients had Karnofsky Performance Scores 
